ALK-Abelló Logo

ALK-Abelló

Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.

ALK | CO

Overview

Corporate Details

ISIN(s):
DK0061802139
LEI:
529900SGCREUZCZ7P020
Country:
Denmark
Address:
Bøge Alle 6-8, 2970 Hørsholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ALK-Abelló is a global pharmaceutical company specializing in the research, development, and manufacturing of allergy immunotherapy (AIT) products. A pioneer in the field for over a century, the company focuses on creating treatments that address the underlying cause of allergies, rather than merely managing symptoms. Its portfolio encompasses a range of evidence-based AIT products, including tablets, drops, and injections, as well as emergency treatments for severe allergic reactions like anaphylaxis. ALK's primary therapeutic areas are respiratory allergies, food allergies, and anaphylaxis. The company is committed to scientific innovation and expanding access to its solutions, such as needle-free adrenaline treatments, to improve the lives of people with allergies worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 17:17
Regulatory News Service
Danish 102.5 KB
2025-11-12 17:17
Earnings Release
Danish 3.3 KB
2025-11-12 17:17
Regulatory News Service
English 104.1 KB
2025-11-12 17:17
Earnings Release
English 2.8 KB
2025-09-17 09:44
M&A Activity
Danish 174.5 KB
2025-09-17 09:44
M&A Activity
Danish 10.0 KB
2025-09-17 09:44
M&A Activity
English 8.9 KB
2025-09-17 09:44
M&A Activity
English 274.6 KB
2025-08-21 07:30
Earnings Release
English 11.5 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Earnings Release
English 12.0 KB
2025-08-12 14:45
Earnings Release
Danish 103.0 KB
2025-08-12 14:45
Earnings Release
Danish 3.7 KB
2025-08-12 14:45
Earnings Release
English 108.6 KB

Automate Your Workflow. Get a real-time feed of all ALK-Abelló filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALK-Abelló

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ALK-Abelló via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Viking Therapeutics, Inc. Logo
Biopharma developing novel therapies for metabolic and endocrine disorders like obesity and NASH.
United States of America
VKTX
Virbac Logo
Develops animal health pharma, vaccines & diagnostics for vets, farmers & pet owners globally.
France
FR000
Vir Biotechnology, Inc. Logo
Immunology company developing antibody therapies for serious infectious diseases and cancer.
United States of America
VIR
Viridian Therapeutics, Inc.\DE Logo
Develops antibody therapies for rare autoimmune diseases, primarily Thyroid Eye Disease (TED).
United States of America
VRDN
ViroGates A/S Logo
Develops suPAR diagnostic tests for inflammation risk assessment in acute care and longevity.
Denmark
VIRO
Vistagen Therapeutics, Inc. Logo
Biopharma firm developing intranasal therapies for anxiety, depression & neurological disorders.
United States of America
VTGN
Vistin Pharma Logo
A leading global producer of Metformin Hydrochloride for the global healthcare market.
Norway
VISTN
Vita 34 AG Logo
A cell bank storing umbilical cord stem cells as biological insurance for families' future health.
Germany
V3V
Vivani Medical, Inc. Logo
Develops long-term subdermal drug implants for chronic diseases like diabetes & weight management.
United States of America
VANI
Vivoryon Therapeutics N.V. Logo
Developing first-in-class small molecule therapies for age-related and kidney diseases.
Germany
VVY

Talk to a Data Expert

Have a question? We'll get back to you promptly.